The device is made from a proprietary material known as STAR, which is notable for its anti-fibrotic and anti-inflammatory properties. In July 2022, AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize MINIject, providing support for iSTAR Medical's development and commercial efforts while expanding AbbVie's eye care business. The company is aiming to seek market approval in the US.
Cyborg Score Rationale
Clinical trials indicate MINIject achieves a mean IOP reduction of over 40% at two years post-surgery. Founded in 2010, the company has raised $60.8M in funding from investors like Capricorn Partners, SRIW and Gimv. The July 2022 AbbVie strategic alliance de-risks commercialization efforts and provides global market access infrastructure.
Top Insights
MINIject is available for sale in the European Union, the UK, Norway, Iceland, Switzerland and Australia.
The company is currently enrolling a U.S. Pre-Market Approval study (STAR-V) to enable commercialization in the U.S.
MINIject showed sustained 5-year efficacy in glaucoma treatment (April 2025).
The company has 11 investors including Capricorn Venture Partners, Namur Invest, Capricorn Partners and Societe Regionale du Investissement de Wallonie.
Named Competitors
Ocular Therapeutix — MIGS devices and sustained-release glaucoma therapies
Nova Eye Medical — Minimally invasive glaucoma surgery implants
LIQID Medical — Glaucoma surgical devices
Ciliatech — Ophthalmic implant technology
Recent Developments
(April 2025) Five-year safety and efficacy results of MINIject demonstrated in STAR-GLOBAL trial
(July 2022) Strategic alliance announced with AbbVie for development and commercialization of MINIject
(January 2024) Successful first implants completed in Australia, expanding international commercial rollout
Open the full interactive iSTAR Medical report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.